Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2014

Shiga toxin/verocytotoxin-producing Escherichia coli infections: practical clinical perspectives

T. K. Davis

Washington University School of Medicine

Nicole C.A. J. Van De Kar

Radboud University Medical Centre

Phillip I. Tarr

Washington University School of Medicine

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Davis, T. K.; Van De Kar, Nicole C.A. J.; and Tarr, Phillip I., "Shiga toxin/verocytotoxin-producing Escherichia coli infections: practical clinical perspectives." *Microbiology Spectrum*. 2, 4. (2014).

https://digitalcommons.wustl.edu/open_access_pubs/4731

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Shiga Toxin/Verocytotoxin-Producing *Escherichia coli* Infections: Practical Clinical Perspectives

T. KEEFE DAVIS,¹ NICOLE C. A. J. VAN DE KAR,² and PHILLIP I. TARR³

¹Division of Nephrology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110; ²Division of Nephrology, Department of Pediatrics, Radboud University Medical Centre, Nijmegen, The Netherlands; ³Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, and Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110

ABSTRACT *Escherichia coli* strains that produce Shiga toxins/verotoxins are rare, but important, causes of human disease. They are responsible for a spectrum of illnesses that range from the asymptomatic to the life-threatening hemolytic-uremic syndrome; diseases caused by *E. coli* belonging to serotype O157:H7 are exceptionally severe. Each illness has a fairly predictable trajectory, and good clinical practice at one phase can be inappropriate at other phases. Early recognition, rapid and definitive microbiology, and strategic selection of tests increase the likelihood of good outcomes. The best management of these infections consists of avoiding antibiotics, antimotility agents, and narcotics and implementing aggressive intravenous volume expansion, especially in the early phases of illness.

INTRODUCTION

Shiga toxin (Stx)-producing *Escherichia coli* (STEC) cause illness with a spectrum of severity ranging from mild (even asymptomatic) carriage to life-threatening disease (1–3). STEC infections are relatively uncommon; in the United States, extrapolation of data from FoodNet (4) to a nationwide population that exceeds 300,000,000 indicates there are fewer than 4,000 diagnosed cases of *E. coli* O157:H7 infection per annum. *E. coli* O157:H7 remains the near-exclusive cause of hemolytic-uremic syndrome (HUS) throughout most of the world, and the single serotype on which most data have been generated. Therefore, we emphasize this particular pathogen in this

article. The European Food Safety Authority and the European Centre for Disease Prevention and Control report similar epidemiology: 4,000 confirmed infections caused by Stx-producing *E. coli* strains (mostly belonging to the O157 serogroup) in 27 European Union member states. The number of reported infections attributed to *E. coli* strains that produce Shiga toxins has increased since 2008 (5).

Despite their low overall incidence, human infections are medically and epidemiologically actionable. The rarity with which Shiga toxin-producing *E. coli* infections occur, barriers to timely microbial diagnosis, consequences of missed diagnoses, and the many difficulties in attempts to generate high-quality evidence on which to justify treatments pose challenges for clinicians and public health systems. In this review, we focus on clinical aspects (i) early in illness; (ii) in the intermediate stage of

Received: 8 January 2014, **Accepted:** 22 January 2014,
Published: 15 August 2014

Editors: Vanessa Sperandio, University of Texas Southwestern Medical Center, Dallas, TX, and Carolyn J. Hovde, University of Idaho, Moscow, ID

Citation: Davis TK, Van De Kar NCAJ, Tarr PI. 2014. Shiga toxin/verocytotoxin-producing *Escherichia coli* infections: practical clinical perspectives. *Microbiol Spectrum* 2(4):EHEC-0025-2014. doi:10.1128/microbiolspec.EHEC-0025-2014.

Correspondence: Phillip I. Tarr, tarr@wustl.edu

© 2014 American Society for Microbiology. All rights reserved.

illness as HUS evolves in the approximately 15 to 20% of infected children in whom this complication occurs; and (iii) during the HUS phase and its aftermath. When data exist, we cite the appropriate literature, but in other circumstances, we rely on our cumulative experience, as noted.

DEFINITIONS

This field of study has been vexed by multiple nomenclature issues. In this review and in our own papers and practice, we describe the toxins produced by enteric pathogens that cause HUS as Shiga toxins (Stxs). This term is synonymous with verocytotoxins (VT), named for the toxic effect of these proteins on Vero cells, as originally described by Konawalchuk et al. (6) and identified as the key phenotype of these pathogens by Karmali et al. (7). *E. coli* strains that produce Stx are termed Stx-producing *E. coli* (STEC), which is synonymous with VT-producing *E. coli* (VTEC). However, in this text we use the term STEC/VTEC when describing bacteria that produce Stx/VT. This combined term reflects our current misgivings about the term Stx to refer to the cardinal virulence trait of these pathogens. These misgivings are rooted in a practical matter: many physicians, on learning that their patient is infected with a Shiga toxin-producing organism, assume erroneously that the laboratory is describing an infection with *Shigella* sp. (4). Such misconceptions are, in our experience, preludes to the inappropriate administration of antibiotics.

Enterohemorrhagic *E. coli* (EHEC) is another term for STEC/VTEC strains that cause human disease. This term is also problematic, because it implies that the diarrhea stools contain visible blood, which is sometimes not the case in *E. coli* O157:H7 infections, and frequently not the case in infections caused by STEC/VTEC strains belonging to other serotypes. Furthermore, a small subset of patients with HUS will have no diarrhea, but their stool will nevertheless contain *E. coli* O157:H7 (8, 9).

We also have preferences for clinical descriptors related to STEC/VTEC infection. In lieu of the time-honored term hemorrhagic colitis (coined in the first outbreak report) (10), we prefer the more encompassing concept of “bloody diarrhea.” For HUS, we urge a urinalysis-independent, stringent case definition, consisting of the simultaneous presence of nonimmune hemolytic anemia (hematocrit/packed cell volume <30% with smear evidence of hemolysis and a negative Coombs test), thrombocytopenia (platelet count <150,000 mm³), and azotemia (creatinine > upper limit of normal for age) (11). There is much hazard and little benefit to be gained

from using less stringent clinical definitions of this complication of STEC/VTEC infections. For example, reliance on an abnormal urinalysis to define HUS, especially if the serum creatinine is normal, risks consideration of incorrect diagnoses such as urinary tract infections, especially as the possibility of contamination with fecal material is high in the setting of diarrhea. Moreover, these widely available blood tests enable physicians to relate their patient’s course to those described in many other studies during the past 3 decades from multiple countries (12–31).

HISTORY

HUS was first described in the mid-1950s by Gasser et al. (32). In that series of 10 fatal illnesses, cases 3 and 4 had “Brechdurchfall,” which is vomiting plus diarrhea (case 3 had these signs throughout the entire illness, while the diarrhea of case 4 occurred only preterminally). None of the other clinical courses suggested enteric illnesses, and notably none of the reports used the terms bloody diarrhea or dysentery. However, we have found earlier papers describing cases in which diarrhea or dysentery preceded renal failure and death within a time frame that closely resembles that of *E. coli*-related HUS (33–37).

E. coli O157:H7 and the closely related pathogen *E. coli* O157:H[−] were estimated to have split from the same progenitor about 7,000 years ago (38). This common ancestor acquired a gene encoding Stx2/VT2 before that. However, it was not until the 1970s when *E. coli* that had been isolated from food was reported to produce Stx/VT (6). This phenotype preceded by several years the first description of STEC/VTEC strains as causes of disease in 1983. In that year, near-simultaneous publications introduced these pathogens to the medical community: Riley et al. described a hamburger-associated outbreak of *E. coli* O157:H7 infections (10), and Karmali et al. linked fecal STEC/VTEC to HUS (7). Also in 1983, additional investigators demonstrated the production of Stx/VT by *E. coli* O157:H7 (39–42).

DISTINCTION BETWEEN STEC/VTEC BELONGING TO SEROTYPE O157:H7 AND THOSE BELONGING TO ALL OTHER SEROTYPES

There are important practical reasons to differentiate STEC/VTEC strains that express the O (somatic) 157 and flagellar (H) 7 antigens from all other serotypes, which we collectively term non-O157:H7 STEC/VTEC. Most compellingly, *E. coli* O157:H7 is the STEC/VTEC

that remains to this day the near-exclusive cause of postdiarrheal HUS (8, 12, 16, 21, 43–49). This serotype is also the one most strongly associated with outbreaks (though most infections are sporadic). If stool specimens are handled adroitly (i.e., immediately transported to the laboratory and inoculated on sorbitol-MacConkey agar on receipt), the microbiologist can often inform the clinician of a presumptive positive or negative for this serotype within 18 to 24 h. That simple piece of information provides valuable clarity to the management of patients with acute diarrhea. However, because a proportion of STEC/VTEC infections are caused by non-O157:H7 STEC/VTEC, there is considerable merit to also determining their presence, but it is much more imperative to exert the greatest effort to confirm or refute the presence of *E. coli* O157:H7 in a stool culture. One important exception to this statement exists: sorbitol-fermenting *E. coli* O157:H[−] is as virulent, or possibly more virulent, than *E. coli* O157:H7 (50), and this clone remains endemic in Germany. These organisms, which are closely related to *E. coli* O157:H7 (38), are not detected by sorbitol-MacConkey agar screening.

E. coli O157:H7 is best detected in stool by using sorbitol-MacConkey agar with or without cefixime-tellurite (51), because unlike most commensal *E. coli* and non-O157:H7 STEC/VTEC strains, *E. coli* O157:H7 does not ferment sorbitol after overnight incubation. Hence, the presence of a colorless colony on sorbitol-MacConkey agar that agglutinates with an appropriate serologic reagent enables the microbiologist to make a confident and timely presumptive diagnosis. For inexplicable reasons, *E. coli* O157:H7 is more easily detected by sorbitol-MacConkey agar plating than by toxin testing of broth cultures of stool (1, 16, 52–56). Because of the greater sensitivity of agar plating, the critical importance of making a diagnosis of *E. coli* O157:H7 infection as rapidly as possible, and the recognition that a small subset of non-O157:H7 STEC/VTEC infections can be severe, we agree with the guidance of the Centers for Disease Control and Prevention that advises the simultaneous testing for *E. coli* O157:H7 (on agar plates) and non-O157:H7 STEC/VTEC (using, in most cases, a toxin enzyme immunoassay [EIA]) (57). We strongly disagree with detection algorithms that assume that the EIA can be used as a screen with sorbitol-MacConkey agar plating only for positives. Such protocols underdetect *E. coli* O157:H7 and delay answering an important question: is the patient infected with *E. coli* O157:H7 or not?

Though non-O157:H7 STEC/VTEC can cause HUS, the likelihood that any non-O157:H7 STEC/VTEC

infection will result in serious kidney injury is extremely low. As noted above, *E. coli* O157:H7 is the overwhelming cause of postdiarrheal HUS (8, 12, 16, 21, 43–49). If the stool of a patient with HUS does not contain *E. coli* O157:H7, the most likely explanation is that the specimen was first cultured for this organism at a point in illness when the pathogen had been eliminated (44).

Table 1 summarizes the *E. coli* O157:H7/non-O157:H7 STEC/VTEC acuity pyramid derived from several defined populations (the HUS studies are globally distributed, but the non-HUS cohorts are from the United States). As illness severity increases, inferred from the setting of acquisition of culture (large geographic region to emergency facility to cohorts with HUS), the ratio of non-O157:H7 STEC/VTEC to *E. coli* O157:H7 diminishes. Findings from several of these studies are particularly worth mentioning. Of 229 Connecticut patients with infections caused by non-O157:H7 STEC/VTEC who were studied over a decade-long interval (48), HUS developed in only one, while HUS developed in 45 of the 434 patients in this series who were infected with *E. coli* O157. In a United States-wide study of 83 patients with HUS (12), 70 patients had stool cultures in which bacteria grew. These specimens were obtained a median of 8 days after illness onset. Of the 30 STEC/VTEC strains identified in these 30 specimens, 25 were *E. coli* O157. Of the five patients whose stools yielded non-O157:H7 STEC/VTEC, four had serologic testing in convalescence and three of them had antibody evidence of recent exposure to the O157 lipopolysaccharide antigen. Hence, an EIA (or, increasingly, PCR) (58, 59) to detect an STEC/VTEC strain, when added to sorbitol MacConkey agar screening, is likely to lead to the diagnosis of cases that are at much lower risk of HUS developing. Nonetheless, making a diagnosis in at least a subset of these cases is worthwhile, if for no other reason than to provide etiologic clarity to an

TABLE 1 Acuity pyramid. Frequency of recovery of *E. coli* O157:H7 and non-O157:H7 STEC/VTEC, according to the setting of acquisition of specimen

Setting and study years	<i>E. coli</i> O157:H7	Non-O157:H7 STEC/VTEC
Wide geographic areas (1998–2009) (48, 141)	Montana: 38% Connecticut: 42%	Montana: 62% Connecticut: 58%
Pediatric emergency facilities (1991–2005) (1, 16, 142)	71%	29%
HUS (1984–2010) (8, 12, 16, 21, 43–49)	95–99%	1–5%

illness that is usually of greater severity than most gastroenteritides. However, data do not exist to calculate the overall value or cost of such policies, but, again, sorbitol-MacConkey agar screening is most crucial to include when performing stool cultures for bacterial pathogens.

CLINICAL MANAGEMENT OF STEC/VTEC INFECTIONS: PRE-HUS PHASE

Our approach to STEC/VTEC infections is based on three overarching principles:

1. Early detection is critical: time is not on your side when treating STEC/VTEC infections.
2. Early and vigorous volume expansion is associated with avoidance of the most severe renal injury.
3. Highly strategic test selection avoids generating misleading and potentially harmful results.

Early identification (and hospitalization) of infected patients is critical because it lowers the risk of secondary cases (60), avoids diagnostic misadventures (for example, we have seen patients started on steroids because of presumed fulminant ulcerative colitis), and facilitates the commencement of intravenous volume expansion. Several lines of evidence suggest that renal perfusion is threatened prior to and during HUS and that diminished kidney blood flow increases the likelihood of severe renal injury. First, there is evidence of prothrombotic abnormalities in the infected host before HUS (and even if HUS does not ensue). Factor 1.2 (the prothrombin activation peptide), D-dimers, plasminogen activator inhibitor, and platelet-activating factor are each elevated during *E. coli* O157:H7 infections, and von Willebrand's factor is also sheared (indicating flow-related rheological stress, probably caused by nascent thrombi) (13, 17, 61). These prothrombotic abnormalities, which are demonstrated at a point in illness when the blood counts are normal, probably produce some degree of renal ischemia, even before there is smear evidence of microangiopathy. Second, if HUS develops, dehydration at presentation (manifest as elevated hemoglobin) is associated with less favorable short-term (62–64) and long-term (65) outcomes. Third, intravenous volume expansion early in illness, starting as soon as possible after presentation, is associated with less severe (i.e., nonanuric) HUS, if HUS ensues (20, 21).

The details of our fluid management protocols are provided in reference 66. We have slightly changed our recommendations (articulated in reference 66) to now suggest complete blood counts every 12 h until there is

assurance that the hemoglobin is falling with volume expansion, because we have not found other indices of circulating blood volume (BUN:creatinine ratio, skin turgor, or vital signs) to be reliable in this setting (authors' personal experience). We aim for a decrement in the hemoglobin of 0.5 g/dL per each 12-h period over the first 1 or 2 days. It can be difficult to accurately assess host volume status, and there is a risk of overload with vigorous volume expansion, so we stress the importance of assiduous monitoring of infected children in centers that are adept at pediatric care (20, 66).

Antibiotics were first suggested as potentially increasing the risk of HUS developing in the initial report linking STEC/VTEC infection to this disorder (7). No credible evidence has emerged since then that supports the concept that antibiotics administered to children or adults early in illness reduce the likelihood of HUS subsequently developing. In fact, extensive data from multiple studies, including more than 1,000 patients infected in epidemics and sporadically, demonstrate that antibiotics are at best neutral and quite likely increase the risk of HUS developing (Table 2). Indeed, the largest risk is demonstrated in the studies with the most robust data: large cohorts, interviewed prospectively, with extensive analysis of timing of administration of antibiotics, and representing infections with multiple different strains.

We also urge against the use of narcotics and anti-diarrheal agents in patients with infections that could be caused by STEC/VTEC because of their association with higher rates of HUS or neurological sequelae (67, 68). We also do not endorse nonsteroidal anti-inflammatory agents, because, in our experience, they have no value and because of their nephrotoxic potential (69), which might be exacerbated in the dehydrated state (70).

Early in HUS Prognostic Factors

HUS occurs in 15 to 20% of children who are culture positive for *E. coli* O157:H7. Several indicators apparent early in the course of HUS are associated with a severe course of HUS. A combination of hypocalcemia (≤ 2 mmol/L) plus oliguria (urine output < 0.4 mL kg⁻¹ h⁻¹ for 24 h) within 48 h of hospitalization had the highest predictive value for negative outcomes (death, need for dialysis, hypertension requiring therapy, or central nervous system sequelae at discharge) (71). Multiple seizures, coma, retinal hemorrhages, hyperkalemia (> 7.5 mmol/L), acidosis (bicarbonate < 8 mmol/L), or a diastolic blood pressure > 90 mm Hg are also suggested to be early indicators of poor outcome in HUS (72). An elevated polymorphonuclear leukocyte count in

diarrhea-associated HUS is also a risk factor for poor outcome (73, 74). Unfortunately, these risk factors and biomarkers were measured at different points of illness, often after poor outcomes are becoming self-evident. Nonetheless, the greatest determinant of short- (75) and long-term (62, 76–87) outcome of *E. coli*-related acute kidney injury remains oligoanuria.

HUS with and without Oligoanuria

There are two categories of HUS: oligoanuric and non-oligoanuric. We emphasize the importance of averting oligoanuria to the extent possible, because of the repeated associations between chronic renal sequelae and presence and duration of oligoanuria during HUS (62, 76–87). In reality, oligoanuric HUS is equivalent to anuric HUS (though there can be a day of oliguria before renal shutdown is complete). Anuria probably reflects acute tubular necrosis. The mechanism of acute tubular necrosis in STEC/VTEC HUS is not completely established but could represent either the effect of Shiga toxin on renal tubules (88–91) or ischemia secondary to thrombotic occlusion of the renal vasculature (92). In view of the abundant evidence of prothrombotic activation before azotemia ensues, and in consideration of examples of diminished renal blood flow preceding anuric renal response in many other clinical situations, we have tended to favor the occlusive/ischemic mechanism as the cause of anuria in HUS. As noted above, oligoanuric HUS has categorically worse short- and long-term implications for patients.

HUS that requires dialysis occurs in up to 71% of patients, according to a summary of HUS series over the past 4 years (Table 3). The median length of stay after the case definition of HUS is attained is 12 days for patients with oligoanuria versus 6 days for patients with nonoligoanuric renal failure (20). Dialysis should be instituted soon after anuria onset to prevent cardiopulmonary overload, avoid electrolyte disturbances, and treat hypertension. Early initiation of dialysis if anuria develops allows the provision of nutrition without exacerbating the above complications.

In our institutions, peritoneal dialysis is the most commonly used modality although intermittent hemodialysis and continuous renal replacement therapies are equally effective. From our perspective, there are several reasons to use peritoneal dialysis in HUS, including avoiding unnecessary care in the intensive care unit (decreasing cost) and allowing direct access to peritoneal fluid, which is helpful if the possibility of bowel perforation is raised. If necessary, home renal replacement can be used in the event of delayed recovery.

Renal replacement therapies, i.e., peritoneal and hemodialysis, are the chief supportive modalities in oligoanuric HUS. A review of these interventions is beyond the scope of this chapter. However, some complications of dialysis seem to be relatively frequent during HUS. First, as we recently reviewed (93), infectious complications of peritoneal dialysis are common. Catheter malfunction, probably related to bowel wall and mesenteric edema, also complicates peritoneal dialysis during HUS. Catheter failure typically presents when a catheter infuses dialysate but does not drain. Catheter malfunction often obligates surgical replacement or conversion to hemodialysis. For hemodialysis, we recommend a dual-lumen catheter of age-appropriate size, preferably in the internal jugular vein. The authors generally use regional citrate anticoagulation of the extracorporeal circuit, but systemic heparin anticoagulation can also be used. Invasive procedures, such as peritoneal dialysis catheter and central vascular line placements, can be performed safely without excessive bleeding during the thrombocytopenia of HUS; platelet transfusions are rarely necessary (94, 95).

Fluid and Electrolyte Abnormalities during HUS

There are numerous electrolyte disturbances associated with acute HUS. Hyponatremia, hyperkalemia or hypokalemia, hypocalcemia, and hypoalbuminemia are common. Notably, however, these abnormalities usually by themselves do not obligate dialysis if urine is still being produced (96). Fatalities in the absence of anuria are exceptionally rare, and recent retrospective data suggesting the value of early renal replacement therapy if children are >10% overloaded probably do not apply to the still urinating child with HUS (97). Hyperuricemia is common, as is elevated lactate, and could be related to diminished renal flow, impaired clearance, and increased production (98).

Hypertension

Hypertension during and after acute HUS is common, with up to 70% of patients affected (99). The mechanism of HUS-induced hypertension is multifactorial and likely related to volume overload and to endothelial and vascular injury. Renovascular hypertension has been suggested to play a role, but plasma renin activity during HUS is below age-appropriate norms (100) (but renal vein renin concentrations have not been determined in this situation). We have had excellent success using calcium channel blockers in acute HUS. If hypertension is present at discharge, we use angiotensin-converting enzyme inhibition even if the creatinine has not yet

TABLE 2 Summary of antibiotic experience in multiple case control studies of children and adults^a

Study	Year performed, setting	Ages of patients	Predominant antibiotics given	Details provided regarding day of illness on which antibiotics were administered (timing), and comments	HUS rate in group receiving antibiotics	HUS rate in group not receiving antibiotic
Carter (143)	1985 Outbreak analysis, Canada	16–67 yr old	Amoxicillin, tetracycline	Timing not specified. Outbreak characterized by two phases: primary, contaminate food; secondary, person-to-person transmission. Antibiotic therapy within the 2 days before food exposure (primary phase) did not have increased risk of HUS developing. However, those on antibiotics during the outbreak (secondary phase) had a 10.3 relative risk of HUS developing.	Does not specify ^b	Does not specify ^b
Pavia et al. (144)	1988 Outbreak, case-control study, Utah	6–39 yr old	Predominantly trimethoprim-sulfamethoxazole	Timing not specified. Comment: All antimicrobial agents were begun with 72 h after onset of diarrhea.	5/8 (63%)	0/7 (0%)
Proulx (145)	1989–1990 Randomized controlled trial, Canada, antibiotics administered late in illness	5 ± 4 yr (average)	Trimethoprim-sulfamethoxazole (1)	Yes	2/22 (8%)	4/25 (16%)
Bell et al. (67)	1993 Outbreak, retrospective cohort, Washington State	<16 yr old	Trimethoprim-sulfamethoxazole (62%), ampicillin or amoxicillin (26%), cephalosporins (12%), metronidazole (8%)	Yes	8/50 (16%)	28/218 (13%)
Wong et al. (146) (superseded by reference 31 described below)	1997–1999 Multistrain, prospective cohort study, four states	<10 yr old	Trimethoprim-sulfamethoxazole (2/5), β-lactams (3/5)	Yes	5/9 (56%)	5/62 (8%)

Dundas et al. (147)	1996 Outbreak, retrospective cohort study, Scotland	18 mo to 94 yr old Mean = 63	Ciprofloxacin	Timing not specified. Comment: HUS developed in 8 (57%) of the 14 patients who received any antibiotic in the 4 wk prior to the outbreak. HUS developed in 7 (47%) of 15 cases treated with ciprofloxacin ≤ 4 days after symptom onset compared to 25% of the 104 cases that did not receive antibiotic treatment (the difference was not statistically significant).	8/14 (57%) treated with antibiotics in the 4 wk before illness onset 7/15 (47%) treated with antibiotics within 4 days after illness onset	26/104 (25%)
Wong et al. (31) (extended cohort analysis of reference 146 described above)	1997–2006 Multistrain, prospective cohort study, five states	<10 yr old	Trimethoprim-sulfamethoxazole (9/25), β -lactams (9/25), metronidazole (3/25), azithromycin (4/25)	Yes	9/25 (36%)	27/234 (12%)
Smith et al. (148).	1996–2002 Multistrain, age matched, case-case comparison	<20 yr old	β -lactams (22% case, 4% control), sulfonamides (14% case, 24% control), metronidazole (6% case, 2% control)	Timing partly specified. Subjects received antibiotics in two specific periods: within the first 3 days after diarrhea onset and in the first 7 days after diarrhea onset.	27/63 ^c (43%)	38/125 (30%) ^c
Cimolai et al. (68)	1984–1989 Multistrain, sporadic cases, retrospective cohort study, British Columbia, Canada	Age range not reported. HUS cohort: mean = 49 mo Gastroenteritis cohort: mean = 83 mo	Agents not specified, but were characterized as “appropriate” if antimicrobial was recognized to be effective in the treatment of shigellosis and if isolate was susceptible in vitro testing.	Timing not specified. Duration of antibiotic use termed “short” if ≤ 24 h or prolonged if >24 h.	14.3% ^d	4.4% ^d

^aModified from reference 93 with permission.

^bRisk ratio in lieu of HUS rate was provided, and was 8.5 (95% confidence interval 2.7–27.5) in favor of antibiotics associated with HUS development.

^cResults report the exposure of antibiotics within the first 7 days.

^dResults limited to “appropriate” antibiotics administered for short terms.

TABLE 3 Severity of HUS in series identified in PubMed published between 2009 and 2013, using search terms hemolytic-uremic syndrome AND children, on September 4, 2013^a

Year of cases, reference	Site	Age group	Dialysis rate	Fatalities	Comments
1997–2006 (31)	Washington, Oregon, Idaho, Wyoming, and Missouri	N = 36, <10 yr	31%	0	Many of these patients were well hydrated (i.e., a subset were among those in a single center series [20] at the onset of HUS, which could account for the low dialysis rate).
2007–2008 (21)	California, Washington, Missouri, Ohio, Wisconsin, Arkansas, Indiana, Glasgow, New Mexico, Tennessee	N = 50, <18 yr	68%	0	
1994–2010 (149)	Alberta, Canada	N = 124, <18 yr	43%	2%	This case series employed a case definition of HUS that did not obligate azotemia. Hence, the low dialysis rate might reflect patients who would not have been considered to have had HUS in other series, and demonstrates another reason to avoid urinalysis-dependent definitions of HUS.
1998–2008 (150)	Buenos Aires, Argentina	N = 365, Ages not reported	43%	(Not reported)	94% of patients underwent peritoneal dialysis; 24% peritonitis rate
1995–2011 (62)	Buenos Aires, Argentina	N = 137, Ages not reported	52%	(Not reported)	Better hydration during the prodromal phase was associated with lower frequencies of oligoanuria and need for dialysis.
2011 (30)	Hamburg, Germany	N = 90, <18 yr	71%	1.1%	Outbreak of HUS caused by <i>E. coli</i> O104:H4. Outcomes and severity resembled those of <i>E. coli</i> O157:H7 HUS.

^aOnly articles with diarrhea associated HUS and dialysis rates are included.

normalized, provided the serum creatinine concentration is falling and the patient is not on dialysis.

Hematologic Complications during HUS

Almost all patients with HUS require erythrocyte transfusions because of hemolysis. The basis for the hemolysis is presumably physical shearing as red cells course through small vessels in which fibrin thrombi are abundant. Transfusion requirements appear independent of the severity of the renal injury (authors' personal observations). We use cardiopulmonary compromise or tachycardia as an indication for transfusion, rather than an arbitrary hemoglobin concentration, though in reality it is common to factor in the rate of hemolysis, time of day, vascular access, and point in illness. The transfusion requirement can continue several days beyond resolution of thrombocytopenia and return of creatinine to normal (authors' personal observations).

Several additional elements should be considered when pondering the need for erythrocyte transfusion. First, erythrocyte life span is short in HUS, ranging between 8 and 24 days (101), and the fibrin debris presumably recedes on a day-by-day basis. Hence, transfused red cells might last longer if transfusion can be delayed until needed. Second, we try to use an entire

unit at each transfusion. Third, we have frequently noted hypertension immediately following transfusion, so antihypertensive medications should be readily available. After transfusion needs abate, we usually do not provide iron to correct the residual anemia because the total body iron is not low; reticulocyte counts might be helpful in this situation.

We also rarely transfuse platelets because the underlying process leading to thrombocytopenia is most likely entrapment of platelets in thrombi, and thrombocytes have short circulating half-lives in HUS (101). Also, HUS is a thrombotic process, which is not well served by platelet transfusions. It is also concerning that most HUS-related strokes are thrombotic and not hemorrhagic (102, 103). Fibrinogen turnover is not increased in HUS as it is in classic consumptive coagulopathies (101). We therefore recommend against requesting disseminated intravascular coagulation laboratory tests as they are not likely to provide relevant information.

Neurologic Complications during HUS

HUS can be associated with a variety of bona fide neurologic lesions, and signs and symptoms of central nervous system dysfunction have been reported in 20 to 50% of cases. HUS has an apparent predilection for

causing basal ganglia lesions (104), but every structure of the brain can be affected (105, 106). The most common serious neurologic complications of HUS are coma, convulsions, and strokes. These complications are usually poor prognostic signs but are rarely by themselves lethal. Possible mechanisms for these complications include endothelial injury with microthrombotic formation and hypoxia. Neurological dysfunction may be further exacerbated by hyponatremia, hypertension, and uremia. Although involvement of the central nervous system might portend a poor prognosis, it must be appreciated that neurologic recovery can be delayed for weeks or months, even after exceptionally severe HUS (107–110). Indeed, in comprehensive studies of survivors of HUS who were infected during the 2011 outbreak of *E. coli* O104:H4 infections, children and adults usually made complete neurologic recoveries even after exceptionally severe neurologic abnormalities during the acute phase (30, 111, 112).

Patients infected with STEC/VTEC often are irritable, lethargic, and jittery, and we do not treat these signs. It is possible that the around-the-clock defecations during the pre-HUS phase contribute to their occurrence.

The use of sedatives to prevent patient movement is not recommended, because the mental status of patients with HUS is often altered and such sedation might confound clinical assessment. Acetaminophen and, if necessary, fentanyl are our preferred analgesics. Morphine should be avoided because of the neurotoxic effects of its metabolites, which are cleared by the kidneys (113, 114).

Additional nonnephrologic complications of HUS are summarized in Table 4.

Chronic Renal-Related Sequelae of HUS

The precise risk of long-term consequences of HUS is difficult to gauge. A meta-analysis of 49 papers including 3,476 patients from 18 countries estimated incidences of death at 9% and end-stage renal disease at 3%, but most of these two outcomes occurred during acute HUS (86). In the same paper, a meta-analysis of 2,372 patients with a minimum of 1 year follow-up estimated 8%, 6%, and 1.8% of patients who have recovered from HUS will have a glomerular filtration rate (per 1.73 m²) of 60–80, 30–59, and 5–29 ml min^{−1}. In this same group, 10% had hypertension and 15% had proteinuria. Meta-regression

TABLE 4 Selected nonnephrologic, nonhematologic complications of HUS

Complication	Comments	References
Pancreatitis	Do not pursue mild ("chemical") pancreatitis by extensive investigation or withholding oral intake. Hyperlipasemia and hyperamylasemia could be related to intestinal and not biliary injury, emesis, and diminished renal clearance.	151
Diabetes mellitus	Insulin dependence can be transient during acute HUS, or persist following renal improvement, or rarely present in the convalescent phase.	152–157
Intestinal perforation and necrosis	These complications are often difficult to identify. Acidosis that fails to resolve with dialysis suggests a severe intestinal complication warranting a laparotomy.	158
Biliary lithiasis	This is usually apparent in the several weeks after HUS resolves and is manifest as right upper quadrant pain and rarely biliary obstruction. This is probably caused by massive hemolysis and subsequent pigment load in the biliary system during HUS.	152, 153
Irritable bowel syndrome	This can occur after STEC/VTEC infections, as with other bacterial enteric infections. Its prognosis is good, often resolving within a year.	159
Elevated transaminases	These might reflect liver injury or, possibly, arise from hemolysis. There is rarely actionable liver injury during HUS.	160
Bowel obstruction	Post-HUS strictures can occur in the small or large bowel. One of the authors is aware of a postinfectious stricture occurring in an adult in whom HUS did not develop, but this complication usually is manifest in the several weeks or months after HUS resolves. These are best detected by contrast studies (small bowel follow-through or barium enema studies).	161, 162
Cardiac ischemia and/or myocarditis	This complication is unusual but can complicate HUS. Troponin determination and cardiac ultrasound might be helpful. We have noted late in illness, i.e., as HUS resolves, complications in elderly patients with HUS.	9, 163
Retinal hemorrhages	Ocular abnormalities are rarely sought in young children, so frequency might be higher than has been appreciated. Long-term complications included decreased visual acuity and optic nerve atrophy.	164, 165
Acute respiratory distress syndrome and pulmonary hemorrhage	Pulmonary hemorrhage is a poor prognostic factor.	9, 64
Sudden death	This complication is rare. Case reports occurring during the acute phase of illness.	163, 166, 167

analysis indicated the severity of illness and the presence of central nervous system symptoms were associated with worse outcomes. Full renal recovery was not achieved if dialysis exceeded 4 weeks, but we have seen patients who have made nearly complete recoveries after such prolonged anuria. There are profound selection biases in computing chronic sequelae rates if the cohorts are limited to those patients who are still returning to follow-up years after HUS. It is also important to note that it is not clear how clinically relevant many of these sequelae (such as microalbuminuria) are, and in our experience, chronic renal failure later in life after normalization of the serum creatinine is exceedingly unusual. However, it is important to note that a recurring set of data suggests that presence and duration of oligoanuria are major predictors of chronic renal sequelae (62, 76–87), reinforcing the need to avoid this complication during acute HUS, if at all possible.

Use of Plasmapheresis and Eculizumab

Eculizumab administration and therapeutic plasma exchange during the large German outbreak in 2011 ignited debate about using these modalities in *E. coli*-related HUS. Eculizumab prevents formation of the membrane attack complex by inhibiting C5 function, and its use has been prompted by a letter to the *New England Journal of Medicine* (115). However, HUS in each of the patients described in that letter was already resolving (decreasing lactate dehydrogenase and/or rising platelet counts) when eculizumab was started. Several in vitro and animal experiments suggest activation of complement after exposure to Stx/VT (116–118), but these experiments employed STEC/VTEC concentrations several orders of magnitude higher than the levels that have ever been documented in humans (119). In contrast, a primate model of lethal STEC/VTEC challenge demonstrated no evidence of complement activation (120). Finding evidence of alternate complement pathway activation in children with HUS is not evidence of a pathogenic role for this branch of the innate immune system (121), as complement is often activated in multisystem organ injury, such as trauma (122). Finally, there are potentially deleterious effects of inhibiting complement during HUS, most notably sepsis (123).

There is similarly no justification for therapeutic plasma exchange in *E. coli*-related HUS. There is no credible evidence of deficiency in functional ADAMTS13, the enzyme that catalyzes shearing of von Willebrand's factor into less thrombogenic forms, inhibitors of this enzyme (i.e., an antibody), or circulating ultra-large

von Willebrand's factor multimers, which suggests a lesion that might be treated with plasma therapies (124–126). Analyses of the *E. coli* O104:H4 outbreak provided no evidence of the value of eculizumab and plasma exchange (127–129). Risks of plasma exchange include complications of catheter insertion, hypocalcemia, and exposure to blood products (130). It is important to remember that patients with HUS often deteriorate after they are initially diagnosed, that the median number of days of anuria (among those whose urine output ceases) is 8 (20), and that gradual spontaneous resolution of the microangiopathy and recovery of renal and neurologic function are the rule and not the exceptions. Creative treatments offer no benefit to standard, assiduous, intensive care monitoring but do carry risks of adverse events. Such interventions should not be conducted outside the context of controlled trials, and only if sufficient data exist to suggest a state of clinical equipoise as to their potential value. Therapeutic plasma exchange and anticomplement therapies do not meet this standard in *E. coli*-related HUS.

Clinical Pitfalls in HUS

Postdiarrheal HUS overwhelmingly occurs on a tightly choreographed trajectory (131): diarrhea (usually painful) evolves into grossly bloody diarrhea (80 to 85% of the time). All three criteria for HUS are usually met between the 5th and 13th day of illness, with the first day of diarrhea assigned to be the first day of illness. However, opportunities for Type 1 and 2 diagnostic errors arise because many different microangiopathic disorders have at least some laboratory and historic elements in common with *E. coli*-related HUS, and microbial diagnosis of *E. coli*-related HUS is often elusive.

Type 1 diagnostic errors (i.e., falsely assuming a patient has *E. coli*-related HUS when the patient's microangiopathy is caused by another process) generally occur in patients with aberrant prodromes to renal failure (minimal or no diarrhea, or chronic diarrhea), or laboratory values that are inconsistent with a diagnosis of *E. coli*-related HUS. This problem is compounded by look-alike disorders that do not have highly stereotypical presentations so are more difficult to recognize. Type 2 diagnostic errors (i.e., incorrectly assuming a patient does not have *E. coli*-related HUS) generally relate to lost microbiologic diagnostic opportunities. To avoid Type 1 errors, we search for other etiologies of microangiopathy if there is a persistent documented fever in a health care setting; exceptionally long (>10 days)

or short (<5 days) prodromal illnesses; prominent respiratory symptoms or findings; hypotension/shock; family history (especially of distant past episodes) (132); the patient is under 6 months of age, uses specific medications (e.g., oral contraceptives, cyclosporine), is pregnant; or there are discordances between renal injury (severe) and hematologic abnormalities (minimal anemia or thrombocytopenia). The gastrointestinal symptoms that accompany thrombotic thrombocytopenic purpura (133) or atypical HUS caused by complement regulatory proteins (134, 135) rarely resemble those of the enteric prodrome of STEC/VTEC-related HUS, and for this reason, we do not routinely seek other disorders if the presentation is typical. Adjunctive tests, which should be requested and interpreted with circumspection, include chest X rays, blood and urine cultures (and testing for Shiga toxin production if an *E. coli* bacterium is isolated), assays for ADAMTS13 activity, and complement regulatory protein gene sequencing (135–137). Tests that are not helpful diagnostically and often misleading include serum C3, C4, and total hemolytic complement. In our experience with HUS, Type 2 diagnostic errors are more common than Type 1 errors, and are often based on the misconception that failing to find evidence of an STEC/VTEC infection proves that such an etiologic agent is absent. It is important to note that microbiology testing early in illness has the highest yield for STEC/VTEC and that many children with HUS are culture negative at the time of presentation with HUS (44). We strive to increase the microbiologic yield by performing a rectal swab culture on admission of all children with HUS, attempting to take possession of specimens the earliest in illness (usually agar plates), and seeking STEC/VTEC in these specimens in our own centers' microbiology laboratories. Serology, i.e., seeking evidence of circulating immunoglobulins to the O157 lipopolysaccharide (or to the lipopolysaccharide of several other serogroups), can also be used to assign etiology to cases of HUS in patients in whom a pathogen has not been recovered from the stool (138, 139). Antibodies to VT/Stx are less frequently sought, but newer enzyme immunoassays might offer greater ease of performance (140). However, serologic testing is not widely available. Also, absence of diarrhea does not exclude the possibility of an STEC/VTEC infection (8, 9), and finding such a pathogen can avert a much more extensive evaluation and therapeutic misadventures. Therefore, in any atypical presentation of a microangiopathic disorder we nevertheless exclude, to the best of our ability, an etiologic agent by either culture or serologic investigation.

SUMMARY

E. coli O157:H7 remains the most exceptional pathogen among the STEC/VTEC group, in view of its enduring association with HUS worldwide, its leading frequency in case series of STEC/VTEC infections (compared to any other serotype), and its ability to cause epidemics as well as sporadic cases. Agar plating of all incoming stools is the best way to detect this pathogen. Early in illness, aggressive volume expansion is associated with reduced renal injury. Specific therapies directed at this pathogen or its products are either harmful (antibiotics) or unlikely to work (the toxemia is short lived). Therapeutic plasma exchange and complement inhibition are not justified by credible data.

ACKNOWLEDGMENTS

Cepheid has paid P. I. Tarr an honorarium for a lecture at its headquarters on this topic. Some work in his laboratory is supported by a grant to another investigator at Washington University from Alexion Corporation (manufacturers of eculizumab). N.C. A. J. van de Kar is a member of the International Advisory Board of aHUS, Alexion Corporation.

We are grateful to families, patients, and collaborators for teaching us much about gut infections and HUS over the past 3 decades. We thank Ariana Jasarevic for expert manuscript assistance, Alexander Weymann for translating original literature from German to English, and Vikas Dharnidharka for providing helpful comments during the creation of this manuscript.

REFERENCES

1. Denno DM, Shaikh N, Stapp JR, Qin X, Hutter CM, Hoffman V, Mooney JC, Wood KM, Stevens HJ, Jones R, Tarr PI, Klein EJ. 2012. Diarrhea etiology in a pediatric emergency department: a case control study. *Clin Infect Dis* 55:897–904.
2. Watanabe H, Terajima J, Izumiya H, Wada A, Tamura K. 1999. Molecular analysis of enterohemorrhagic *Escherichia coli* isolates in Japan and its application to epidemiological investigation. *Pediatr Int* 41:202–208.
3. Stephan R, Untermann F. 1999. Virulence factors and phenotypical traits of verotoxin-producing *Escherichia coli* strains isolated from asymptomatic human carriers. *J Clin Microbiol* 37:1570–1572.
4. Gould LH, Mody RK, Ong KL, Clogher P, Cronquist AB, Garman KN, Lathrop S, Medus C, Spina NL, Webb TH, White PL, Wymore K, Gierke RE, Mahon BE, Griffin PM, Emerging Infections Program Foodnet Working Group. 2013. Increased recognition of non-O157 Shiga toxin-producing *Escherichia coli* infections in the United States during 2000–2010: epidemiologic features and comparison with *E. coli* O157 infections. *Foodborne Pathog Dis* 10:453–460.
5. European Food Safety Authority. 2012. The European Union Summary Report on Trends and Sources of Zoonoses, Zoonotic Agents and Food-borne Outbreaks in 2010. *EFSA Journal* 10:161–188.
6. Konowalchuk J, Speirs JL, Stavric S. 1977. Vero response to a cytotoxin of *Escherichia coli*. *Infect Immun* 18:775–779.
7. Karmali MA, Steele BT, Petric M, Lim C. 1983. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing *Escherichia coli* in stools. *Lancet* 1:619–620.
8. Miceli S, Jure MA, de Saab OA, de Castillo MC, Rojas S, de Holgado AP, de Nader OM. 1999. A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina. *Jpn J Infect Dis* 52:33–37.

9. Brandt JR, Fouser LS, Watkins SL, Zelikovic I, Tarr PI, Nazar-Stewart V, Avner ED. 1994. *Escherichia coli* O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers. *J Pediatr* 125:519–526.
10. Riley LW, Remis RS, Helgeson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, Blake PA, Cohen ML. 1983. Hemorrhagic colitis associated with a rare *Escherichia coli* serotype. *N Engl J Med* 308:681–685.
11. Meites S, Buffone GJ. 1989. *Pediatric Clinical Chemistry: Reference (Normal) Values*. AACC Press, Washington, DC.
12. Banatvala N, Griffin PM, Greene KD, Barrett TJ, Bibb WF, Green JH, Wells JG, Hemolytic Uremic Syndrome Study Collaborators. 2001. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. *J Infect Dis* 183:1063–1070.
13. Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI. 2001. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in *Escherichia coli* O157:H7-associated hemolytic uremic syndrome. *Pediatr Res* 49:653–659.
14. Jelacic S, Wobbe CL, Boster DR, Ciol MA, Watkins SL, Tarr PI, Stapleton AE. 2002. ABO and P1 blood group antigen expression and stx genotype and outcome of childhood *Escherichia coli* O157:H7 infections. *J Infect Dis* 185:214–219.
15. Cornick NA, Jelacic S, Ciol MA, Tarr PI. 2002. *Escherichia coli* O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome. *J Infect Dis* 186:57–63.
16. Klein EJ, Stapp JR, Clausen CR, Boster DR, Wells JG, Qin X, Swerdlow DL, Tarr PI. 2002. Shiga toxin-producing *Escherichia coli* in children with diarrhea: a prospective point-of-care study. *J Pediatr* 141:172–177.
17. Smith JM, Jones F, Ciol MA, Jelacic S, Boster DR, Watkins SL, Williams GD, Tarr PI, Henderson WR, Jr. 2002. Platelet-activating factor and *Escherichia coli* O157:H7 infections. *Pediatr Nephrol* 17:1047–1052.
18. Thayu M, Chandler WL, Jelacic S, Gordon CA, Rosenthal GL, Tarr PI. 2003. Cardiac ischemia during hemolytic uremic syndrome. *Pediatr Nephrol* 18:286–289.
19. Jelacic JK, Damrow T, Chen GS, Jelacic S, Bielaszewska M, Ciol M, Carvalho HM, Melton-Celsa AR, O'Brien AD, Tarr PI. 2003. Shiga toxin-producing *Escherichia coli* in Montana: bacterial genotypes and clinical profiles. *J Infect Dis* 188:719–729.
20. Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI. 2005. Relative nephroprotection during *Escherichia coli* O157:H7 infections: association with intravenous volume expansion. *Pediatrics* 115:e673–680.
21. Hickey CA, Beattie TJ, Cowieson J, Miyashita Y, Strife CF, Frem JC, Peterson JM, Butani L, Jones DP, Havens PL, Patel HP, Wong CS, Andreoli SP, Rothbaum RJ, Beck AM, Tarr PI. 2011. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. *Arch Pediatr Adolesc Med* 165:884–889.
22. Zimmerhackl LB, Rosales A, Hofer J, Riedl M, Jungtraithmayr T, Mellmann A, Bielaszewska M, Karch H. 2010. Enterohemorrhagic *Escherichia coli* O26:H11-associated Hemolytic uremic syndrome: bacteriology and clinical presentation. *Semin Thromb Hemost* 36:586–593.
23. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB. 2002. Clinical course and the role of shiga toxin-producing *Escherichia coli* infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. *J Infect Dis* 186:493–500.
24. Bielaszewska M, Middendorf B, Kock R, Friedrich AW, Fruth A, Karch H, Schmidt MA, Mellmann A. 2008. Shiga toxin-negative attaching and effacing *Escherichia coli*: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution. *Clin Infect Dis* 47:208–217.
25. Bielaszewska M, Kock R, Friedrich AW, von Eiff C, Zimmerhackl LB, Karch H, Mellmann A. 2007. Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm? *PLoS One* 2:e1024.
26. Friedrich AW, Zhang W, Bielaszewska M, Mellmann A, Kock R, Fruth A, Tschape H, Karch H. 2007. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic *Escherichia coli* O157 infection in humans. *Clin Infect Dis* 45:39–45.
27. Bielaszewska M, Friedrich AW, Aldick T, Schurk-Bulgrin R, Karch H. 2006. Shiga toxin activatable by intestinal mucus in *Escherichia coli* isolated from humans: predictor for a severe clinical outcome. *Clin Infect Dis* 43:1160–1167.
28. Sonntag AK, Prager R, Bielaszewska M, Zhang W, Fruth A, Tschape H, Karch H. 2004. Phenotypic and genotypic analyses of enterohemorrhagic *Escherichia coli* O145 strains from patients in Germany. *J Clin Microbiol* 42:954–962.
29. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. 1999. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying *Escherichia coli* O157:H7 infection. *Clin Nephrol* 52:357–362.
30. Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Hartel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Muller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, König J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ. 2012. An outbreak of Shiga toxin-producing *Escherichia coli* O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. *Clin Infect Dis* 55:753–759.
31. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. 2012. Risk factors for the hemolytic uremic syndrome in children infected with *Escherichia coli* O157:H7: a multivariable analysis. *Clin Infect Dis* 55:33–41.
32. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. 1955. [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. *Schweiz Med Wochenschr* 85:905–909.
33. Fahr T. 1925. Kreislaufstörungen in der Niere, p. 121–155. In Fahr T, Gruber G, Koch M, Lubarsch O, Stoerk O (ed.), *Harnorgane Männliche Geschlechtsorgane*, vol. 6. Springer, Vienna, Austria.
34. Bamforth J. 1923. A case of symmetrical cortical necrosis of the kidneys occurring in an adult man. *J Pathol Bacteriol* 26:40–45.
35. Campbell AC, Henderson JL. 1949. Symmetrical cortical necrosis of the kidneys in infancy and childhood. *Arch Dis Child* 24:269–285, illust.
36. Dunn JS, Montgomery GL. 1941. Acute necrotising glomerulonephritis. *J Pathol Bacteriol* 52:1–16.
37. Hensley WJ. 1952. Haemolytic anaemia in acute glomerulonephritis. *Australas Ann Med* 1:180–185.
38. Leopold SR, Magrini V, Holt NJ, Shaikh N, Mardis ER, Cagno J, Ogura Y, Iguchi A, Hayashi T, Mellmann A, Karch H, Besser TE, Sawyer SA, Whittam TS, Tarr PI. 2009. A precise reconstruction of the emergence and constrained radiations of *Escherichia coli* O157 portrayed by backbone concatenomic analysis. *Proc Natl Acad Sci USA* 106:8713–8718.
39. O'Brien AO, Lively TA, Chen ME, Rothman SW, Formal SB. 1983. *Escherichia coli* O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. *Lancet* 1:702.
40. O'Brien AD, LaVeck GD, Thompson MR, Formal SB. 1982. Production of Shigella dysenteriae type 1-like cytotoxin by *Escherichia coli*. *J Infect Dis* 146:763–769.
41. Johnson WM, Lior H, Bezanson GS. 1983. Cytotoxic *Escherichia coli* O157:H7 associated with haemorrhagic colitis in Canada. *Lancet* 1:76.
42. O'Brien AD, LaVeck GD. 1983. Purification and characterization of a Shigella dysenteriae 1-like toxin produced by *Escherichia coli*. *Infect Immun* 40:675–683.
43. Neill MA, Tarr PI, Clausen CR, Christie DL, Hickman RO. 1987. *Escherichia coli* O157:H7 as the predominant pathogen associated with

the hemolytic uremic syndrome: a prospective study in the Pacific Northwest. *Pediatrics* 80:37–40.

44. Tarr PI, Neill MA, Clausen CR, Watkins SL, Christie DL, Hickman RO. 1990. *Escherichia coli* O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. *J Infect Dis* 162:553–556.

45. Rowe PC, Orrbine E, Lior H, Wells GA, Yetisir E, Clulow M, McLaine PN. 1998. Risk of hemolytic uremic syndrome after sporadic *Escherichia coli* O157:H7 infection: results of a Canadian collaborative study. Investigators of the Canadian Pediatric Kidney Disease Research Center. *J Pediatr* 132:777–782.

46. Rivas M, Miliwebsky E, Chinen I, Roldan CD, Balbi L, Garcia B, Fiorilli G, Sosa-Estani S, Kincaid J, Rangel J, Griffin PM, Case-Control Study Group. 2006. Characterization and epidemiologic subtyping of Shiga toxin-producing *Escherichia coli* strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. *Foodborne Pathog Dis* 3:88–96.

47. Pollock KG, Young D, Beattie TJ, Todd WT. 2008. Clinical surveillance of thrombotic microangiopathies in Scotland, 2003–2005. *Epidemiol Infect* 136:115–121.

48. Hadler JL, Clogher P, Hurd S, Phan Q, Mandour M, Bemis K, Marcus R. 2011. Ten-year trends and risk factors for non-O157 Shiga toxin-producing *Escherichia coli* found through Shiga toxin testing, Connecticut, 2000–2009. *Clin Infect Dis* 53:269–276.

49. Mody RK, Luna-Gierke RE, Jones TF, Comstock N, Hurd S, Scheffel J, Lathrop S, Smith G, Palmer A, Strockbine N, Talkington D, Mahon BE, Hoekstra RM, Griffin PM. 2012. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing *Escherichia coli*. *Arch Pediatr Adolesc Med* 166:902–909.

50. Werber D, Bielaszewska M, Frank C, Stark K, Karch H. 2011. Watch out for the even eviler cousin-sorbitol-fermenting *E coli* O157. *Lancet* 377:298–299.

51. Chapman PA, Siddons CA. 1996. A comparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producing *Escherichia coli* O157 from cases of bloody diarrhoea, non-bloody diarrhoea and asymptomatic contacts. *J Med Microbiol* 44:267–271.

52. Fey PD, Wickert RS, Rupp ME, Safranek TJ, Hinrichs SH. 2000. Prevalence of non-O157:H7 shiga toxin-producing *Escherichia coli* in diarrheal stool samples from Nebraska. *Emerg Infect Dis* 6:530–533.

53. Carroll KC, Adamson K, Korgenski K, Croft A, Hankemeier R, Daly J, Park CH. 2003. Comparison of a commercial reversed passive latex agglutination assay to an enzyme immunoassay for the detection of Shiga toxin-producing *Escherichia coli*. *Eur J Clin Microbiol Infect Dis* 22:689–692.

54. Manning SD, Madera RT, Schneider W, Dietrich SE, Khalife W, Brown W, Whittam TS, Somsel P, Rudrik JT. 2007. Surveillance for Shiga toxin-producing *Escherichia coli*, Michigan, 2001–2005. *Emerg Infect Dis* 13:318–321.

55. Teel LD, Daly JA, Jerris RC, Maul D, Svanas G, O'Brien AD, Park CH. 2007. Rapid detection of Shiga toxin-producing *Escherichia coli* by optical immunoassay. *J Clin Microbiol* 45:3377–3380.

56. Park CH, Kim HJ, Hixon DL, Bubert A. 2003. Evaluation of the duopath verotoxin test for detection of shiga toxins in cultures of human stools. *J Clin Microbiol* 41:2650–2653.

57. Gould LH, Bopp C, Strockbine N, Atkinson R, Baselski V, Body B, Carey R, Crandall C, Hurd S, Kaplan R, Neill M, Shea S, Somsel P, Tobin-D'Angelo M, Griffin PM, Gerner-Smidt P, Centers for Disease Control and Prevention (CDC). 2009. Recommendations for diagnosis of shiga toxin-producing *Escherichia coli* infections by clinical laboratories. *MMWR Recomm Rep* 58:1–14.

58. Gryns TE, Sloan LM, Rosenblatt JE, Patel R. 2009. Rapid and sensitive detection of Shiga toxin-producing *Escherichia coli* from nonenriched stool specimens by real-time PCR in comparison to enzyme immunoassay and culture. *J Clin Microbiol* 47:2008–2012.

59. Vallieres E, Saint-Jean M, Rallu F. 2013. Comparison of three different methods for detection of Shiga toxin-producing *Escherichia coli* in a tertiary pediatric care center. *J Clin Microbiol* 51:481–486.

60. Werber D, Mason BW, Evans MR, Salmon RL. 2008. Preventing household transmission of Shiga toxin-producing *Escherichia coli* O157 infection: promptly separating siblings might be the key. *Clin Infect Dis* 46:1189–1196.

61. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI. 2002. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. *N Engl J Med* 346:23–32.

62. Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. 2012. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. *Pediatr Nephrol* 27:1407–1410.

63. Coad NA, Marshall T, Rowe B, Taylor CM. 1991. Changes in the postenteropathic form of the hemolytic uremic syndrome in children. *Clin Nephrol* 35:10–16.

64. Oakes RS, Siegler RL, McReynolds MA, Pysker T, Pavia AT. 2006. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. *Pediatrics* 117:1656–1662.

65. Ojeda JM, Kohout I, Cuestas E. 2013. Dehydration upon admission is a risk factor for incomplete recovery of renal function in children with haemolytic uremic syndrome. *Nefrologia* 33:372–376.

66. Holtz LR, Neill MA, Tarr PI. 2009. Acute bloody diarrhea: a medical emergency for patients of all ages. *Gastroenterology* 136:1887–1898.

67. Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI. 1997. Predictors of hemolytic uremic syndrome in children during a large outbreak of *Escherichia coli* O157:H7 infections. *Pediatrics* 100:E12.

68. Cimolai N, Basalyga S, Mah DG, Morrison BJ, Carter JE. 1994. A continuing assessment of risk factors for the development of *Escherichia coli* O157:H7-associated hemolytic uremic syndrome. *Clin Nephrol* 42:85–89.

69. Misurac JM, Knoderer CA, Leiser JD, Nailescu C, Wilson AC, Andreoli SP. 2013. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. *J Pediatr* 162:1153–1159, 1159 e1.

70. John CM, Shukla R, Jones CA. 2007. Using NSAID in volume depleted children can precipitate acute renal failure. *Arch Dis Child* 92:524–526.

71. Havens PL, O'Rourke PP, Hahn J, Higgins J, Walker AM. 1988. Laboratory and clinical variables to predict outcome in hemolytic-uremic syndrome. *Am J Dis Child* 142:961–964.

72. Vitacco M, Sanchez Avalos J, Gianantonio CA. 1973. Heparin therapy in the hemolytic-uremic syndrome. *J Pediatr* 83:271–275.

73. Walters MD, Matthei IU, Kay R, Dillon MJ, Barratt TM. 1989. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. *Pediatr Nephrol* 3:130–134.

74. Milford DV, Staten J, MacGreggor I, Dawes J, Taylor CM, Hill FG. 1991. Prognostic markers in diarrhoea-associated haemolytic-uraemic syndrome: initial neutrophil count, human neutrophil elastase and von Willebrand factor antigen. *Nephrol Dial Transplant* 6:232–237.

75. Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. 2014. Laboratory predictors of acute dialysis in hemolytic uremic syndrome. *Pediatr Int* 56:234–239.

76. Dolislager D, Tune B. 1978. The hemolytic-uremic syndrome: spectrum of severity and significance of prodrome. *Am J Dis Child* 132:55–58.

77. Gianantonio CA, Vitacco M, Mendilaharsu F, Gallo GE, Sojo ET. 1973. The hemolytic-uremic syndrome. *Nephron* 11:174–192.

78. Gianantonio CA, Vitacco M, Mendilaharsu F, Gallo G. 1968. The hemolytic-uremic syndrome. Renal status of 76 patients at long-term follow-up. *J Pediatr* 72:757–765.

79. Tonshoff B, Sammet A, Sanden I, Mehls O, Waldherr R, Scharer K. 1994. Outcome and prognostic determinants in the hemolytic uremic syndrome of children. *Nephron* 68:63–70.

80. Siegler RL, Pavia AT, Christofferson RD, Milligan MK. 1994. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. *Pediatrics* 94:35–40.
81. Mizusawa Y, Pitcher LA, Burke JR, Falk MC, Mizushima W. 1996. Survey of haemolytic-uraemic syndrome in Queensland 1979–1995. *Med J Aust* 165:188–191.
82. Spizzirri FD, Rahman RC, Bibiloni N, Ruscasso JD, Amoreo OR. 1997. Childhood hemolytic uremic syndrome in Argentina: long-term follow-up and prognostic features. *Pediatr Nephrol* 11:156–160.
83. Mencia Bartolome S, Martinez de Azagra A, de Vicente Aymat A, Monleon Luque M, Casado Flores J. 1999. [Uremic hemolytic syndrome. Analysis of 43 cases]. *An Esp Pediatr* 50:467–470. (In Spanish.)
84. Huseman D, Gellermann J, Vollmer I, Ohde I, Devaux S, Ehrich JH, Filler G. 1999. Long-term prognosis of hemolytic uremic syndrome and effective renal plasma flow. *Pediatr Nephrol* 13:672–677.
85. Loirat C. 2001. [Post-diarrhea hemolytic-uremic syndrome: clinical aspects]. *Arch Pediatr* 8 Suppl 4:776s–784s. (In French.)
86. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF. 2003. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. *JAMA* 290:1360–1370.
87. Oakes RS, Kirkham JK, Nelson RD, Siegler RL. 2008. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. *Pediatr Nephrol* 23:1303–1308.
88. Nestoridi E, Kushak RI, Duguerre D, Grabowski EF, Ingelfinger JR. 2005. Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. *Kidney Int* 67:2254–2266.
89. Hughes AK, Stricklett PK, Kohan DE. 1998. Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. *Kidney Int* 54:426–437.
90. Taguchi T, Uchida H, Kiyokawa N, Mori T, Sato N, Horie H, Takeda T, Fujimoto J. 1998. Verotoxins induce apoptosis in human renal tubular epithelium derived cells. *Kidney Int* 53:1681–1688.
91. Kaneko K, Kiyokawa N, Ohtomo Y, Nagaoka R, Yamashiro Y, Taguchi T, Mori T, Fujimoto J, Takeda T. 2001. Apoptosis of renal tubular cells in Shiga-toxin-mediated hemolytic uremic syndrome. *Nephron* 87:182–185.
92. Abuelo JG. 2007. Normotensive ischemic acute renal failure. *N Engl J Med* 357:797–805.
93. Davis TK, McKee R, Schnadower D, Tarr PI. 2013. Treatment of Shiga toxin–Producing *Escherichia coli* infections. *Infect Dis Clin North Am* 27:577–597.
94. Weil BR, Andreoli SP, Billmire DF. 2010. Bleeding risk for surgical dialysis procedures in children with hemolytic uremic syndrome. *Pediatr Nephrol* 25:1693–1698.
95. Balestracci A, Martin SM, Toledo I, Alvarado C, Wainsztein RE. 2013. Impact of platelet transfusions in children with post-diarrheal hemolytic uremic syndrome. *Pediatr Nephrol* 28:919–925.
96. Schulman SL, Kaplan BS. 1996. Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria. *Pediatr Nephrol* 10:671–674.
97. Sutherland SM, Zappitelli M, Alexander SR, Chua AN, Brophy PD, Bunchman TE, Hackbarth R, Somers MJ, Baum M, Symons JM, Flores FX, Benfield M, Askenazi D, Chand D, Fortenberry JD, Mahan JD, McBryde K, Blowey D, Goldstein SL. 2010. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. *Am J Kidney Dis* 55:316–325.
98. Kaplan BS, Thomson PD. 1976. Hyperuricemia in the hemolytic-uremic syndrome. *Am J Dis Child* 130:854–856.
99. Robson WL, Leung AK, Brant R. 1993. Relationship of the recovery in the glomerular filtration rate to the duration of anuria in diarrhea-associated hemolytic uremic syndrome. *Am J Nephrol* 13:194–197.
100. Proesmans W, VanCauter A, Thijs L, Lijnen P. 1994. Plasma renin activity in haemolytic uraemic syndrome. *Pediatr Nephrol* 8:444–446.
101. Katz J, Krawitz S, Sacks PV, Levin SE, Thomson P, Levin J, Metz J. 1973. Platelet, erythrocyte, and fibrinogen kinetics in the hemolytic-uremic syndrome of infancy. *J Pediatr* 83:739–748.
102. Nakahata T, Tanaka H, Tateyama T, Ueda T, Suzuki K, Osari S, Kasai M, Waga S. 2001. Thrombotic stroke in a child with diarrhea-associated hemolytic-uremic syndrome with a good recovery. *Tohoku J Exp Med* 193:73–77.
103. Trevathan E, Dooling EC. 1987. Large thrombotic strokes in hemolytic-uremic syndrome. *J Pediatr* 111:863–866.
104. Steinborn M, Leiz S, Rudisser K, Griebel M, Harder T, Hahn H. 2004. CT and MRI in haemolytic uraemic syndrome with central nervous system involvement: distribution of lesions and prognostic value of imaging findings. *Pediatr Radiol* 34:805–810.
105. Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Pietrement C, Champion G, Ulinski T, Deschenes G. 2010. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 5:1218–1228.
106. Weissenborn K, Donnerstag F, Kielstein JT, Heeren M, Worthmann H, Hecker H, Schmitt R, Schiffer M, Pasedag T, Schuppner R, Tryc AB, Raab P, Hartmann H, Ding XQ, Hafer C, Menne J, Schmidt BM, Bultmann E, Haller H, Dengler R, Lanfermann H, Giesemann AM. 2012. Neurologic manifestations of *E. coli* infection-induced hemolytic-uremic syndrome in adults. *Neurology* 79:1466–1473.
107. Signorini E, Lucchi S, Mastrangelo M, Rapuzzi S, Edefonti A, Fossali E. 2000. Central nervous system involvement in a child with hemolytic uremic syndrome. *Pediatr Nephrol* 14:990–992.
108. Steele BT, Murphy N, Chuang SH, McGreal D, Arbus GS. 1983. Recovery from prolonged coma in hemolytic uremic syndrome. *J Pediatr* 102:402–404.
109. Steinberg A, Ish-Horowitz M, el-Peleg O, Mor J, Branski D. 1986. Stroke in a patient with hemolytic-uremic syndrome with a good outcome. *Brain Dev* 8:70–72.
110. Kahn SI, Tolkan SR, Kothari O, Garella S. 1982. Spontaneous recovery of the hemolytic uremic syndrome with prolonged renal and neurological manifestations. *Nephron* 32:188–191.
111. Magnus T, Rother J, Simova O, Meier-Cillien M, Repenthin J, Moller F, Gbadamosi J, Panzer U, Wengenroth M, Hagel C, Kluge S, Stahl RK, Wegscheider K, Urban P, Eckert B, Glatzel M, Fiehler J, Gerloff C. 2012. The neurological syndrome in adults during the 2011 northern German *E. coli* serotype O104:H4 outbreak. *Brain* 135:1850–1859.
112. Braune SA, Wichmann D, von Heinz MC, Nierhaus A, Becker H, Meyer TN, Meyer GP, Muller-Schulz M, Fricke J, de Weerth A, Hoepker WW, Fiehler J, Magnus T, Gerloff C, Panzer U, Stahl RA, Wegscheider K, Kluge S. 2013. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. *Crit Care Med* 41:1702–1710.
113. Murphy EJ. 2005. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. *Anaesth Intensive Care* 33:311–322.
114. Niscola P, Scaramucci L, Vischini G, Giovannini M, Ferrannini M, Massa P, Tatangelo P, Galletti M, Palumbo R. 2010. The use of major analgesics in patients with renal dysfunction. *Curr Drug Targets* 11:752–758.
115. Lapeyraque AL, Malina M, Fremaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F. 2011. Eculizumab in severe Shiga-toxin-associated HUS. *N Engl J Med* 364:2561–2563.
116. Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Wurzenner R. 2009. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. *J Immunol* 182:6394–6400.

117. Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C. 2011. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. *J Immunol* 187:172–180.
118. Stahl AL, Sartz L, Karpman D. 2011. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic *Escherichia coli*-induced hemolytic uremic syndrome. *Blood* 117:5503–5513.
119. Lopez EL, Contrini MM, Glatstein E, Ayala SG, Santoro R, Ezcurra G, Teplitz E, Matsumoto Y, Sato H, Sakai K, Katsuura Y, Hoshida S, Morita T, Harning R, Brookman S. 2012. An epidemiologic surveillance of Shiga-like toxin-producing *Escherichia coli* infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values. *Pediatr Infect Dis J* 31:20–24.
120. Lee BC, Mayer CL, Leibowitz CS, Stearns-Kurosawa DJ, Kurosawa S. 2013. Quiescent complement in nonhuman primates during *E. coli* Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. *Blood* 122:803–806.
121. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H. 2009. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 4:1920–1924.
122. Ganter MT, Brohi K, Cohen MJ, Shaffer LA, Walsh MC, Stahl GL, Pittet JF. 2007. Role of the alternative pathway in the early complement activation following major trauma. *Shock* 28:29–34.
123. Römer S, Schaumburg R, Karch H, Schwindt W, Waltenberger J, Lebiez P. 2012. Septic shock and ARDS after Eculizumab application in Shiga-toxin associated HUS during the outbreak of Shiga toxin-producing enterohaemorrhagic *E. coli* O104:H4. *Medizinische Klinik, Intensivmedizin und Notfallmedizin* 107:329–330.
124. Tarr PI. 2009. Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis. *Kidney Int Suppl* :S29–S32.
125. Colic E, Dieperink H, Titlestad K, Tepel M. 2011. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. *Lancet* 378:1089–1093.
126. Veyradier A, Obert B, Haddad E, Cloarec S, Nivet H, Foulard M, Lesure F, Delattre P, Lakhdari M, Meyer D, Girma JP, Loirat C. 2003. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. *J Pediatr* 142:310–317.
127. Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Visedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nurnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R, Collaborators of the DGFN STEC-HUS registry. 2012. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing *E. coli* O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. *Nephrol Dial Transplant* 27:3807–3815.
128. Samuelsson O, Follin P, Rundgren M, Rylander C, Selga D, Stahl A. 2012. [The HUS epidemic in the summer of 2011 was severe. German and Swedish experiences of the EHEC outbreak]. *Lakartidningen* 109:1230–1234. (In Swedish.)
129. Nitschke M, Sayk F, Hartel C, Roseland RT, Hauswaldt S, Steinhoff J, Fellermann K, Derad I, Wellhoner P, Buning J, Tiemer B, Katalinic A, Rupp J, Lehnert H, Solbach W, Knobloch JK. 2012. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enterohemorrhagic *Escherichia coli* O104:H4. *JAMA* 307:1046–1052.
130. Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lammle B, George JN, Vesely SK. 2012. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. *Transfusion* 52:2525–2532; quiz 2524.
131. Havens PL, Hoffman GM, Shith KJ. 1989. The homogeneous nature of the hemolytic uremic syndrome. *Clin Pediatr (Phila)* 28:482–483.
132. Kaplan BS, Chesney RW, Drummond KN. 1975. Hemolytic uremic syndrome in families. *N Engl J Med* 292:1090–1093.
133. Karpac CA, Li X, Terrell DR, Kremer Hovinga JA, Lammle B, Vesely SK, George JN. 2008. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. *Br J Haematol* 141:696–707.
134. Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, Komhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC. 2012. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. *Pediatr Nephrol* 27:1283–1291.
135. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. 2010. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol* 5:1844–1859.
136. Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC. 2012. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. *Neth J Med* 70:121–129.
137. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS. 2009. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. *Pediatr Nephrol* 24:687–696.
138. Espie E, Grimont F, Mariani-Kurkdjian P, Bouvet P, Haeghebaert S, Filliol I, Loirat C, Decludt B, Minh NN, Vaillant V, de Valk H. 2008. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing *Escherichia coli* infections in France, 1996–2006. *Pediatr Infect Dis J* 27:595–601.
139. Chart H, Cheasty T. 2008. Human infections with verocytotoxin-producing *Escherichia coli* O157—10 years of *E. coli* O157 serodiagnosis. *J Med Microbiol* 57:1389–1393.
140. Fernandez-Brando RJ, Bentancor LV, Mejias MP, Ramos MV, Exeni A, Exeni C, Laso Mdel C, Exeni R, Isturiz MA, Palermo MS. 2011. Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. *PLoS One* 6:e19136.
141. Close RM, Ejidokun OO, Verlander NQ, Fraser G, Meltzer M, Rehman Y, Muir P, Ninis N, Stuart JM. 2011. Early diagnosis model for meningitis supports public health decision making. *J Infect* 63:32–38.
142. Bokete TN, O'Callahan CM, Clausen CR, Tang NM, Tran N, Moseley SL, Fritsche TR, Tarr PI. 1993. Shiga-like toxin-producing *Escherichia coli* in Seattle children: a prospective study. *Gastroenterology* 105:1724–1731.
143. Carter AO, Borczyk AA, Carlson JA, Harvey B, Hockin JC, Karmali MA, Krishnan C, Korn DA, Lior H. 1987. A severe outbreak of *Escherichia coli* O157:H7-associated hemorrhagic colitis in a nursing home. *N Engl J Med* 317:1496–1500.
144. Pavia AT, Nichols CR, Green DP, Tauxe RV, Mottice S, Greene KD, Wells JG, Siegler RL, Brewer ED, Hannon D, et al. 1990. Hemolytic-uremic syndrome during an outbreak of *Escherichia coli* O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. *J Pediatr* 116:544–551.
145. Proulx F, Turgeon JP, Delage G, Lafleur L, Chicoine L. 1992. Randomized, controlled trial of antibiotic therapy for *Escherichia coli* O157:H7 enteritis. *J Pediatr* 121:299–303.

146. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of *Escherichia coli* O157:H7 infections. *N Engl J Med* 342:1930–1936.
147. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ. 2001. The central Scotland *Escherichia coli* O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. *Clin Infect Dis* 33:923–931.
148. Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. 2012. Antibiotic treatment of *Escherichia coli* O157 infection and the risk of hemolytic uremic syndrome, Minnesota. *Pediatr Infect Dis J* 31:37–41.
149. Grisar S, Morgunov MA, Samuel SM, Midgley JP, Wade AW, Tee JB, Hamiwka LA. 2011. Acute renal replacement therapy in children with diarrhea-associated hemolytic uremic syndrome: a single center 16 years of experience. *Int J Nephrol* 2011:930539.
150. Adragna M, Balestracci A, Garcia Chervo L, Steinbrun S, Delgado N, Briones L. 2012. Acute dialysis-associated peritonitis in children with D+ hemolytic uremic syndrome. *Pediatr Nephrol* 27:637–642.
151. Grodinsky S, Telmesani A, Robson WL, Fick G, Scott RB. 1990. Gastrointestinal manifestations of hemolytic uremic syndrome: recognition of pancreatitis. *J Pediatr Gastroenterol Nutr* 11:518–524.
152. Brandt JR, Joseph MW, Fouser LS, Tarr PI, Zelikovic I, McDonald RA, Avner ED, McAfee NG, Watkins SL. 1998. Cholelithiasis following *Escherichia coli* O157:H7-associated hemolytic uremic syndrome. *Pediatr Nephrol* 12:222–225.
153. Schweighofer S, Jr, Primack WA, Slovis TL, Fleischmann LE, Slovis TL, Hight DW. 1980. Cholelithiasis associated with the hemolytic-uremic syndrome. *Am J Dis Child* 134:622.
154. Suri RS, Mahon JL, Clark WF, Moist LM, Salvadori M, Garg AX. 2009. Relationship between *Escherichia coli* O157:H7 and diabetes mellitus. *Kidney Int Suppl* :S44–S46.
155. U.S. Census Bureau. 2010. 2010 Census Population and Housing Tables (CPH-Ts). <http://quickfacts.census.gov/qfd/states/00000.html>. Accessed on June 18, 2014.
156. Suri RS, Clark WF, Barrowman N, Mahon JL, Thiessen-Philbrook HR, Rosas-Arellano MP, Zarnke K, Garland JS, Garg AX. 2005. Diabetes during diarrhea-associated hemolytic uremic syndrome: a systematic review and meta-analysis. *Diabetes Care* 28:2556–2562.
157. Andreoli SP, Bergstein JM. 1982. Development of insulin-dependent diabetes mellitus during the hemolytic-uremic syndrome. *J Pediatr* 100:541–545.
158. Tapper D, Tarr P, Avner E, Brandt J, Waldhausen J. 1995. Lessons learned in the management of hemolytic uremic syndrome in children. *J Pediatr Surg* 30:158–163.
159. Dundas S, Todd WT. 2000. Clinical presentation, complications and treatment of infection with verocytotoxin-producing *Escherichia coli*. Challenges for the clinician. *Symp Ser Soc Appl Microbiol* :24S–30S.
160. Whittington PF, Friedman AL, Chesney RW. 1979. Gastrointestinal disease in the hemolytic-uremic syndrome. *Gastroenterology* 76:728–733.
161. Yates RS, Osterholm RK. 1980. Hemolytic-uremic syndrome colitis. *J Clin Gastroenterol* 2:359–363.
162. Sawaf H, Sharp MJ, Youn KJ, Jewell PA, Rabbani A. 1978. Ischemic colitis and stricture after hemolytic-uremic syndrome. *Pediatrics* 61:315–317.
163. Abu-Arafah I, Gray E, Youngson G, Auchterlonie I, Russell G. 1995. Myocarditis and haemolytic uraemic syndrome. *Arch Dis Child* 72:46–47.
164. Sturm V, Menke MN, Landau K, Laube GF, Neuhaus TJ. 2010. Ocular involvement in paediatric haemolytic uraemic syndrome. *Acta Ophthalmol* 88:804–807.
165. Siegler RL, Brewer ED, Swartz M. 1988. Ocular involvement in hemolytic-uremic syndrome. *J Pediatr* 112:594–597.
166. Manton N, Smith NM, Byard RW. 2000. Unexpected childhood death due to hemolytic uremic syndrome. *Am J Forensic Med Pathol* 21:90–92.
167. Robson WL, Leung AK, Montgomery MD. 1991. Causes of death in hemolytic uremic syndrome. *Child Nephrol Urol* 11:228–233.